| Latest Achillion Pharmaceuticals News Headlines | | Date | Time | Source | | | 05/17/2007 | 4:02PM | PRNUS | Achillion Announces the Resignation of John C. Pottage, Jr., M.D., Senior Vice President and Chief Medical Officer
NEW HAVEN, Conn., May 17 /PRNewswire-FirstCall/ -- Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) today announced that John C. Pottage, Jr., M.D., Senior Vice President and Chief Medical Officer, has resigned to accept a senior clinical development position at GlaxoSmithKline. His resignation will become effective on... More...>> |
| 05/09/2007 | 7:30AM | PRNUS | Achillion Reports First Quarter 2007 Financial Results
NEW HAVEN, Conn., May 9 /PRNewswire-FirstCall/ -- Achillion Pharmaceuticals, Inc., (NASDAQ:ACHN) a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the quarter ended March 31, 2007.
For the first quarter of 2007... More...>> |
| 04/16/2007 | 8:02AM | PRNUS | Achillion Presents Positive Data on Novel Mechanism for Treating HCV at EASL Annual Meeting
-NS4A Antagonist Demonstrates Clinical Activity, a Novel Mechanism of Action and In Vitro Compatibility with other HCV Inhibitors-
NEW HAVEN, Conn., April 16 /PRNewswire-FirstCall/ -- Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) today announced the presentation of data validating the clinical antiviral activity of... More...>> |
| 03/27/2007 | 4:01PM | PRNUS | Achillion Reports 2006 Fourth Quarter and Year-End Financial Results
NEW HAVEN, Conn., March 27 /PRNewswire-FirstCall/ -- Achillion Pharmaceuticals, Inc., (NASDAQ:ACHN) a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the quarter and year ended December 31, 2006.
For the full year... More...>> |
| 03/21/2007 | 6:30PM | PRNUS | Achillion to Host Fourth Quarter and Year End Investor Conference Call on March 27, 2007
NEW HAVEN, Conn., March 21 /PRNewswire-FirstCall/ -- Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) expects to release its results for the fourth quarter and year ended December 31, 2006 after the market closes on Tuesday, March 27, 2007.
The company will host a conference call to discuss the results at 4:30 PM ET on... More...>> |
| 03/20/2007 | 11:22AM | PRNUS | Achillion to Present at BioCentury and Thomson Financial's 2007 Future Leaders in the Biotech Industry Conference
NEW HAVEN, Conn., March 20 /PRNewswire-FirstCall/ -- Achillion Pharmaceuticals, Inc., (NASDAQ:ACHN) a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Michael D. Kishbauch, Chief Executive Officer of Achillion, will present a corporate... More...>> |
| 02/26/2007 | 2:53PM | PRNUS | Achillion to Present at Upcoming Conferences
NEW HAVEN, Conn., Feb. 26 /PRNewswire-FirstCall/ -- Achillion Pharmaceuticals, Inc., (NASDAQ:ACHN) a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Michael D. Kishbauch, Chief Executive Officer of Achillion, will be presenting... More...>> |
| 02/08/2007 | 4:24PM | PRNUS | Gilead and Achillion Announce Positive Antiviral Activity of NS4A Antagonist in HCV, But Discontinue GS 9132 (ACH-806) Developme
- HCV Collaboration to Continue With Potential New Development Candidates -
FOSTER CITY, Calif. and NEW HAVEN, Conn., Feb. 8 /PRNewswire-FirstCall/ -- Gilead Sciences (NASDAQ:GILD) and Achillion Pharmaceuticals (NASDAQ:ACHN) today announced their decision to discontinue the development of GS 9132, also known as ACH-806... More...>> |
| 11/08/2006 | 4:30PM | PRNUS | Achillion Pharmaceuticals Announces Closing of Underwriters' Over-Allotment Option
NEW HAVEN, Conn., Nov. 8 /PRNewswire-FirstCall/ -- Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) today announced that it closed the sale of an additional 675,000 shares of its common stock in connection with the exercise of the over-allotment option granted to the underwriters of its recent initial public offering of... More...>> |
|